Table 1.

Patient and adoptively transferred cell characteristics

Patient	Age/Sex	Dxa	Sites of Diseaseb	Prior Immunotherapyc	Treatment
					Cell number infused (×10−10)	% NK cellsd	% lysis 888mele	# IL-2 dosesf
1	21/F	MM	Breast, Skin	IL2, IFN	6.45	97	88	6
2	34/F	MM	Hilum	IL2	7.60	96	64	7
3	31/F	MM	Pancreas	IL2	4.20	96	89	7 + 3
4	43/M	MM	LN, Chest Wall, Liver	IL2, IFN, GMCSF	1.88	98	85	6 + 3
5	34/M	MM	Hilum, LN, Lungs	IL2, IFN	3.46	97	67	8 + 6
6	51/M	RCC	Hilum, LN, Lungs	IL2, Sorafenib	6.33	93	100	5 + 5
7	56/M	MM	LN, Lungs	DC vaccine	2.38	97	87	12 + 8
8	42/F	MM	Muscle, LN, SQ, Lungs, Panc.	IL2, DTIC	5.14	95	77	12 + 5

^a“Dx” stands for “diagnosis”; MM indicates metastatic melanoma; RCC indicates renal cell carcinoma.

^b“LN” indicated lymph nodes; “SQ” indicates sub-cutaneous; “Panc.” indicates pancreas.

^c“DC vaccine” indicates dendritic cell vaccine; “DTIC” indicates Dacarbazine

^d% NK cells in the infused cell population was determined by FACS as the % PI- CD3- CD56+ cells.

^eSpecific lysis of 888 melanoma cells by the adoptively transferred cell population was measured using a 4-hour ⁵¹Cr release assays, and the value presented indicates the % specific lysis at a E:T ratio of 10:1.

^fPatients received the indicated number of doses of I.V. IL-2 (720,000 IU/dose). Some patients received a second cycle of IL-2 doses 20 to 27 days after the first treatment as indicated by the “+” sign.